Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: A prospective, randomized crossover study

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 5, 2007, Pages 392-399

  Chappuis, Bernard ^a   Braun, Monika ^a   Stettler, Christoph ^a   Allemann, Sabine ^a   Diem, Peter ^a   Lumb, Peter J ^b   Wierzbicki, Anthony S ^b   James, Richard ^c   Christ, Emanuel R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Pioglitazone; Postprandial metabolism; Rosiglitazone; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG DOSE INCREASE; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; LIPID METABOLISM; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; LIPOPROTEINS; MALE; METFORMIN; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 34447643245     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.715     Document Type: Article

References (32)

1. Taskinen MR. Diabetic dyslipidaemia. From basic research to clinical practice. Diabetologia 2003; 46: 733-749.
2. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997; 17: 3542-3556.
3. Bookstein L, Gidding SS, Donovan M, Smith FA. Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels. Impact on the assessment of risk according to the National Cholesterol Education Program guidelines. Arch Intern Med 1990; 150: 1653-1657.
4. Haffner SM. Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol 2002; 90: 55i-61i.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
6. Allemann S, Diem P, Egger M, Christ ER, Stettler C. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Curr Med Res Opin 2006; 22: 617-623.
7. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
8. Brown BG, Zhao XQ, Chair A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-1592.
9. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926-931.
10. Syvanne M, Hilden H, Taskinen MR. Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. J Lipid Res 1994; 35: 15-26.
11. Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol 2001; 88: 9H-15H.
12. Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002; 45: 461-475.
13. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002; 106: 1211-1218.
14. Rongen GA, Tack CJ. Triglycerides and endothelial function in type 2 diabetes. Eur J Clin Invest 2001; 31: 560-562.
15. Teno S, Uto Y, Nagashima H, et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000; 23: 1401-1406.
16. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
17. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25: 708-711.
18. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164: 2097-2104.
19. Harris JA, Benedict FG. A Biometric Study of Basal Metabolism in Man. Washington DC: Carnegie Institution of Washington: Publ. No 279, 1919.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
21. James RW, Pometta D. Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes 1990; 39: 1158-1164.
22. Olchawa B, Kingwell BA, Hoang A, et al. Physical fitness and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2004; 24: 1087-1091.
23. Duque M, Graupner M, Stutz H, et al. New fluorogenic triacylglycerol analogs as substrates for the determination and chiral discrimination of lipase activities. J Lipid Res 1996; 37: 868-876.
24. Malmstrom R, Packard CJ, Watson TD, et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 1997; 17: 1454-1464.
25. Taskinen MR. Lipoprotein lipase in diabetes. Diabetes Metab Rev 1987; 3: 551-570.
26. Majali KA, Cooper MB, Staels B, Luc G, Taskinen MR, Betteridge DJ. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 2006; 49: 527-537.
27. Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278: 704-711.
28. Narce M, Poisson JP. Novel PPARgamma-dependent and independent effects for thiazolidinediones. Curr Opin Lipidol 2003; 14: 651-652.
29. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
30. Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD. Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res 2003; x20: 1279-1286.
31. Zdunek J, Martinez GV, Schleucher J, et al. Global structure and dynamics of human apolipoprotein CII in complex with micelles: evidence for increased mobility of the helix involved in the activation of lipoprotein lipase. Biochemistry 2003; 42: 1872-1889.
32. Nagashima K, Lopez C, Donovan D, et al. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005; 115: 1323-1332.